Melanotan II is a synthetic cyclic peptide modeled on alpha-melanocyte-stimulating hormone, first developed at the University of Arizona in the 1980s as a potential photoprotective tanning agent. It was never approved as a medicine in any country, yet it circulates widely as a gray-market injectable marketed for tanning and libido. The honest picture separates a plausible biological mechanism from the reality of an unapproved substance sold with no quality control or standardized dosing.
Melanotan II is a synthetic melanocortin-receptor agonist that has never been approved as a medicine in any country and is sold on the gray market as an unregulated injectable for tanning and libido.
Melanotan II is a cyclic seven-amino-acid analogue built from the active core of alpha-MSH, engineered with a ring structure and modified residues that resist the enzymes which break the natural hormone down within minutes. That single change stretches its activity from moments to hours. The broader consequence is its lack of selectivity across the melanocortin receptor family, which is what makes its effects reach well beyond the skin.
Melanotan II is a cyclic seven-amino-acid analogue of alpha-MSH that non-selectively activates the MC1R, MC3R, MC4R, and MC5R melanocortin receptors, producing pigmentation, appetite suppression, and sexual effects at once.
In practice, Melanotan II is used almost entirely off-label and outside any medical setting, and the dominant reason is cosmetic tanning. The original scientific rationale was genuinely protective, but that line of research produced the approved, more selective drug afamelanotide rather than Melanotan II itself, leaving the parent compound to the consumer market.
Melanotan II is used almost entirely off-label for cosmetic tanning and, secondarily, for sexual arousal, obtained through online vendors and social sellers rather than any clinician.
The single most important fact about Melanotan II is that it is not an approved drug in the United States or any other major jurisdiction. Vendors sidestep this by labeling it a "research chemical" or "for research use only," a convention that distances sellers from medical-claims rules but confers no legal legitimacy for human use.
| Jurisdiction | Regulatory status |
|---|---|
| United States (FDA) | Unapproved new drug; illegal to market as a drug or supplement |
| United Kingdom (MHRA) | Unlicensed medicine, illegal to sell for human use |
| Australia (TGA) | Prescription-only, not approved; unauthorized supply is illegal |
| European Union | Unauthorized across member states |
Melanotan II is an unapproved, unlicensed substance in the United States, United Kingdom, Australia, and the European Union, where enforcement falls most heavily on sellers and importers marketing an unlicensed medicine.
Because Melanotan II is unapproved, its safety profile has been characterized through case reports, poison-center data, and small studies rather than the controlled trials an approved medicine would require. That evidentiary gap is itself part of the risk: the long-term picture is largely unstudied, layered on top of a product of unknown identity and dose.
Melanotan II's documented harms range from nausea, flushing, and spontaneous erections to mole darkening that can obscure melanoma signs, with isolated case reports of priapism, rhabdomyolysis, and kidney injury.
There is no approved, validated, or medically endorsed dosing regimen for Melanotan II, because it is not an approved drug. What circulates online are informal user protocols rather than clinical guidance, and describing them is documentation, not endorsement.
No validated or medically endorsed dosing regimen exists for Melanotan II, and circulating protocols describe a subcutaneous loading-then-maintenance pattern on a gray-market product whose concentration and purity vary between batches.
The research record on Melanotan II is thin, dated, and mostly early-stage, and that itself is the important finding. The biology proved real enough to pursue, but the parent compound was set aside in favor of more selective descendants rather than carried through the trials that turn a promising molecule into a licensed medicine.
The evidence base for Melanotan II is limited to small early-phase human trials from the 1990s and early 2000s, with no completed long-term controlled study of its safety or its effects on pigmented skin lesions.
Melanotan II is best understood as the non-selective parent of a small family of melanocortin peptides that were later refined into more targeted, and in two cases approved, drugs. Selectivity is the whole story of the comparison: narrowing the receptor target made the descendants predictable enough to test, dose, and license.
| Peptide | Receptor focus | Approval status |
|---|---|---|
| Melanotan II | Non-selective across MC1R, MC3R, MC4R, MC5R | Never approved; sold gray-market |
| Melanotan I (afamelanotide / Scenesse) | More selective for MC1R pigmentation | Approved for erythropoietic protoporphyria |
| Bremelanotide (PT-141) | Emphasizes the MC4R arousal pathway | Approved for hypoactive sexual desire disorder |
Melanotan II is the non-selective parent compound that remained unapproved, while its more selective relatives afamelanotide and bremelanotide were narrowed to single receptor pathways and successfully approved.
The connection between Melanotan II and skin cancer is one of the most clinically important and most misunderstood parts of the topic. The core danger holds even without a proven causal link, because melanoma detection depends on watching moles for change, and a drug that changes many moles at once disrupts that surveillance.
Melanotan II darkens and changes moles in ways that can mask or mimic melanoma warning signs and interfere with cancer surveillance, even though a direct carcinogenic effect has never been established.
Because Melanotan II is unapproved and sold outside the pharmaceutical supply chain, its quality is not just inconsistent, it is fundamentally unverifiable. No regulator ensures a vial contains what its label states, at the stated amount, free of contaminants, so the pharmacological risks sit on top of a supply that cannot be trusted for identity, dose, or sterility.
Because Melanotan II is sold outside the pharmaceutical supply chain, its identity, dose, and sterility are fundamentally unverifiable, and independent testing has repeatedly found gray-market peptides deviating from their labeled purity.
Educational use only. This article describes what the published scientific and clinical literature reports about Melanotan II. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
